46,860 results match your criteria Psoriasis Pustular


Genus Psoralea A review of the traditional and modern uses, phytochemistry and pharmacology.

J Ethnopharmacol 2018 Dec 3. Epub 2018 Dec 3.

CSIR-National Botanical Research Institute, Plant Transgenic Laboratory, P.O. Box 436, Rana Pratap Marg,Lucknow-226 001, U.P., India. Electronic address:

Ethnopharmacological Relevance: The genus Psoralea (Fabaceae) harbours 105 accepted species that are extensively used by local peoples and medicinal practitioners of China, India, and other countries for treatment of tooth decay, psoriasis, leucoderma, leprosy, kidney problems, tuberculosis, indigestion, constipation and impotence. Presently, pharmacological research reports are available on only few species namely Bituminaria bituminosa (Syn: P. bituminosa), P. Read More

View Article
December 2018
7 Reads

Chondroitin sulfate inhibits secretion of TNF and CXCL8 from human mast cells stimulated by IL-33.

Biofactors 2018 Dec 6. Epub 2018 Dec 6.

Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, Boston, MA, USA.

Glycosaminoglycans (GAGs) are linear, highly negatively charged carbohydrate chains present in connective tissues. Chondroitin sulfate (CS) and heparin (Hep) are also found in the numerous secretory granules of mast cells (MC), tissue immune cells involved in allergic and inflammatory reactions. CS and Hep may inhibit secretion of histamine from rat connective tissue MC, but their effect on human MC remains unknown. Read More

View Article
December 2018

Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.

Acta Derm Venereol 2018 Dec 6. Epub 2018 Dec 6.

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 1, IT-40138 Bologna, Italy.

Nail psoriasis affects 50-79% of patients with skin psoriasis and up to 80% of patients with psoriatic arthritis, and can also represent a negative prognostic factor in individuals with plaque psoriasis. Treatments for nail psoriasis are limited, as nails are often difficult to treat with topical therapies alone, and relapse is common. Among different systemic agents, secukinumab, a fully human monoclonal antibody targeting interleukin (IL)-17A, is the only antibody supported by a trial specifically conducted in patients with nail psoriasis (the TRANSFIGURE trial) and has the longest follow-up available to date. Read More

View Article
December 2018
3 Reads

Systemic therapies of pityriasis rubra pilaris: a systematic review.

J Dtsch Dermatol Ges 2018 Dec 6. Epub 2018 Dec 6.

Department of Dermatology, Venereology, and Allergology, University Medical Centre, Göttingen, Germany.

Pityriasis rubra pilaris (PRP) is a rare papulosquamous disorder. Treatment is challenging; the armamentarium consists of topical corticosteroids, phototherapy, classic systemic treatments such as retinoids or immunosuppressive drugs, and most recently biologicals. However, the relative effectiveness of therapies is unclear. Read More

View Article
December 2018

Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.

J Eur Acad Dermatol Venereol 2018 Dec 6. Epub 2018 Dec 6.

Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany.

Background: Itch is common in psoriasis, adversely affecting health-related quality of life (HRQoL) and sleep.

Objective: We evaluated the efficacy of topical fixed-dose combination calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) on itch, itch-related sleep loss and HRQoL versus foam vehicle. Read More

View Article
December 2018

Metformin inhibits pro-inflammatory responses via targeting nuclear factor-κB in HaCaT cells.

Cell Biochem Funct 2018 Dec 5. Epub 2018 Dec 5.

Department of Dermatology, Chinese PLA General Hospital & Medical School, Beijing, China.

Psoriasis is a prevalent, chronic inflammatory skin disease that arises from rapid and excessive growth of keratinocytes induced by abnormal inflammatory responses. Metformin is the first-line drug in type 2 diabetes and has been proven to possess significant anti-inflammatory effects in various diseases. In the present study, we examined the role of metformin in nuclear factor kappa B (NF-κB)-mediated inflammatory responses in HaCaT cells, a cell line for the keratinocyte. Read More

View Article
December 2018
2 Reads

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.

Psoriasis (Auckl) 2018 13;8:83-92. Epub 2018 Nov 13.

Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal,

Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients' quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab), and most recently IL-17 inhibitors. Risankizumab is a monoclonal antibody which targets IL-23p19 without binding IL-12. Read More

View Article
November 2018
1 Read

Curative Anti-Inflammatory Properties of Chinese Optimized Yinxieling Formula in Models of Parkinson's Disease.

Evid Based Complement Alternat Med 2018 4;2018:6142065. Epub 2018 Nov 4.

Second Clinical Medical College, Guangzhou University of Chinese Medicine, 232 Waihuan Road E, Guangzhou, Guangdong 510006, China.

Parkinson's disease (PD) is marked by the progressive degeneration of dopaminergic neurons (DAN) accompanied by glial activation. Thus, inhibiting glial activation that occurs during this disease could be an effective method for treating PD. Optimized Yinxieling Formula (OYF), a Chinese medicinal formula, which is used to efficiently treat autoimmune disease psoriasis, has been proved to display potential immunomodulatory effects in inflammation-associated diseases. Read More

View Article
November 2018

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain.

Clinicoecon Outcomes Res 2018 12;10:747-759. Epub 2018 Nov 12.

Global Patient Outcomes and Real World Evidence International, Eli Lilly, Surrey, UK.

Background: Currently, several biologic agents are available for the treatment of moderate-to-severe plaque psoriasis, including newer agents with similar mechanisms of action and efficacy; therefore, there is a need to evaluate their efficiency in terms of cost effectiveness.

Objective: This study evaluates the cost effectiveness of recently approved interleukin (IL)-17A antagonists, ixekizumab and secukinumab, for the treatment of moderate-to-severe plaque psoriasis from the perspective of the Spanish National Health System (NHS).

Materials And Methods: A Markov model with a lifetime horizon was developed to compare the cost effectiveness of ixekizumab vs. Read More

View Article
November 2018

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.

Drug Des Devel Ther 2018 12;12:3879-3883. Epub 2018 Nov 12.

Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA,

Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has been primarily developed for use in moderate-to-severe psoriasis. USA-based pharmaceutical company Abbvie submitted it for a Biologics License Application to the US Food and Drug Administration (FDA) in April 2018. Read More

View Article
November 2018

Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies.

Biologics 2018 12;12:151-158. Epub 2018 Nov 12.

Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

Objectives: To describe the therapeutic pathways of patients with psoriasis (PSO) and psoriatic arthritis (PsA) before and after treatment with biological therapies in a real-world setting and to determine the relative consumption of health care resources.

Design: Retrospective observational study.

Setting: Real-life clinical setting in 5 Italian local health units. Read More

View Article
November 2018

Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.

JCI Insight 2018 Dec 6;3(23). Epub 2018 Dec 6.

VEGF-C is an important mediator of lymphangiogenesis and has been shown to alleviate chronic inflammation in a variety of disease models. In this study, we investigated whether targeted delivery of VEGF-C to sites of inflammation and site-specific activation of lymphatic vessels would represent a clinically feasible strategy for treating chronic skin inflammation. To this end, we generated a fusion protein consisting of human VEGF-C fused to the F8 antibody (F8-VEGF-C), which is specific for the alternatively spliced, angiogenesis-marking extradomain A (EDA) of fibronectin. Read More

View Article
December 2018

Evaluation of IL-17 Producing Memory Regulatory and Effector T Cells Expressing CD26 Molecule in Patients with Psoriasis.

Iran J Allergy Asthma Immunol 2018 Oct 14;17(5):453-463. Epub 2018 Oct 14.

Immunology Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran AND Immunology, Asthma and Allergy Research Institute (IAARI), Tehran University of Medical Sciences, Tehran, Iran.

Memory regulatory T cells (Tregs) has been demonstrated to produce IL-17 in Psoriasis. Forkhead box P3 (Foxp3) has been demonstrated not to be reliable marker to evaluate Treg cells. Effector CD4+T cells also express Foxp3 after activation. Read More

View Article
October 2018

A case of co-occurence of Dowling-Degos disease and psoriasis: association or a rarely-seen coincidence?

G Ital Dermatol Venereol 2018 Dec;153(6):884-885

Department of Dermatology, Haseki Training and Research Hospital, Istanbul, Turkey.

View Article
December 2018

Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model.

J Steroid Biochem Mol Biol 2018 Nov 30. Epub 2018 Nov 30.

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, 84105 Beer Sheva, Israel. Electronic address:

Acute myeloid leukemia (AML) is one of the deadliest hematological malignancies without effective treatment for most patients. Vitamin D derivatives (VDDs) - active metabolites 1α,25-dihydroxyvitamin D (1,25D2) and 1α,25-dihydroxyvitamin D (1,25D3) and their analogs - are differentiation-inducing agents which have potential for the therapy of AML. However, calcemic toxicity of VDDs limits their clinical use at doses effective against cancer cells in vivo. Read More

View Article
November 2018
1 Read

Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks.

J Invest Dermatol 2018 Nov 30. Epub 2018 Nov 30.

Kardiologie 1, and DZHK Standort Rhein-Main, Universitätsmedizin Mainz, Mainz, Germany.

Psoriasis increases the risk of cardiovascular (CV) disease. Secukinumab, a fully human monoclonal antibody against IL-17A, shows significant efficacy in psoriasis, but effects on CV markers are unknown. CARIMA was a 52-week, randomized, double-blind, placebo-controlled, exploratory trial in patients with moderate to severe plaque psoriasis without clinical CV disease. Read More

View Article
November 2018

Documenting and defining psoriasis severity: an ongoing challenge.

Authors:
R J G Chalmers

Br J Dermatol 2018 Dec;179(6):1244-1245

Dermatology Centre, The University of Manchester, Manchester, U.K.

View Article
December 2018

Secukinumab for plaque psoriasis.

Medwave 2018 Nov 30;18(7):e7364. Epub 2018 Nov 30.

Proyecto Epistemonikos, Santiago, Chile; Departamento de Dermatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Email: Address: Centro Evidencia UC, Pontificia Universidad Católica de Chile, Diagonal Paraguay 476, Santiago, Chile.

Introduction: Biological treatments have appeared as the main alternative for the management of patients with plaque psoriasis that do not respond to conventional treatment. So, evaluating its actual efficacy and safety is needed.

Methods: We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. Read More

View Article
November 2018
2 Reads

A Drug with Lipophilicity-Dependent Potency Can Be Metabolically Stable: Discovery of a Potent and Selective Retinoic Acid Receptor-Related Orphan Receptor C2 (RORC2) Inverse Agonist as an Orally Bioavailable Anti-Inflammatory Agent.

J Med Chem 2018 Dec 3. Epub 2018 Dec 3.

State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China.

IL-17 drives an amplification mechanism in inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The production of IL-17 depends on the activity of RORC2 in immune cells, which suggests that RORC2 inverse agonists are capable of anti-inflammatory therapy by reducing IL-17 levels. However, oral delivery of inverse agonists remains a challenge since the binding pocket of RORC2 prefers to accommodate lipophilic ligands, which tend to have poor metabolic stability. Read More

View Article
December 2018

Ultraviolet radiation, both UVA and UVB, influences the composition of the skin microbiome.

Exp Dermatol 2018 Dec 2. Epub 2018 Dec 2.

Department of Dermatology, University of Alabama at Birmingham (UAB), Birmingham, AL.

Background: Studies have begun to investigate the complex relationship between host and microorganisms in non-infectious pathologies such as acne, atopic dermatitis, and psoriasis. Though the skin is exposed to environmental stressors such as ultraviolet radiation (UVR), no studies exist examining the effects of both UVA and UVB on the skin microbiome.

Objective: To test the effect of UVA and UVB on human skin microbiome. Read More

View Article
December 2018

Does illness perception associate with disease symptoms in Behçet's disease?

Intern Emerg Med 2018 Nov 30. Epub 2018 Nov 30.

Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey.

This study aims to assess the relationship between illness perception and disease course and symptoms in Behçet disease (BD). One hundred ten consecutive BD patients (F/M 50/60, mean age 38.5 ± 9. Read More

View Article
November 2018

Secukinumab in Generalized Pustular Psoriasis.

Indian Dermatol Online J 2018 Nov-Dec;9(6):464-466

Consultant Dermatologist, Apollo Hospitals, Greams Road, Chennai, Tamil Nadu, India.

View Article
December 2018

Expression of Vascular Endothelial Growth Factor and Microvessel Density in Psoriatic Skin Lesions.

Indian Dermatol Online J 2018 Nov-Dec;9(6):418-421

Department of Dermatology, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, Karnataka, India.

Background: Psoriasis is a common chronic and immune-mediated skin disorder having a significant impact on the patient's quality of life. An analysis of the role of angiogenic vascular endothelial growth factor (VEGF) expression and microvessel density in psoriatic skin lesions may help in better understanding of the disease pathogenesis. The aim of this study was to examine the expression of vascular endothelial growth factor (VEGF) and microvessel density using CD34 antibodies in psoriatic skin lesions by immunohistochemical examination using normal skin of healthy individuals as controls. Read More

View Article
December 2018
1 Read

Narrow-band UVB Phototherapy does not Consistently Improve Quality of Life in Psoriasis Patients: A Prospective Observational Study from Eastern India.

Indian Dermatol Online J 2018 Nov-Dec;9(6):394-404

Department of DVL, Institute of Medical Sciences and SUM Hospital, S'O'A University, Bhubaneswar, Odisha, India.

Introduction: Psoriasis is a chronic inflammatory and proliferative condition of the skin which is well-known to impair the patients' quality of life (QoL). Of the various treatment modalities, narrowband UVB (NBUVB) phototherapy is one of the standard treatments for moderate to severe plaque psoriasis with minimal side-effects compared to other systemic therapies.

Objectives: To study whether NBUVB phototherapy administration improves QoL in plaque-type psoriasis and to find the correlation between clinical severity of psoriasis and patients' QoL by using psoriasis area severity index (PASI), dermatology life quality index (DLQI), and psoriasis disability index (PDI) tools before and after NBUVB phototherapy. Read More

View Article
December 2018

Sleep disorders in patients with psoriatic arthritis and psoriasis.

Reumatologia 2018 31;56(5):301-306. Epub 2018 Oct 31.

Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Poland.

Objectives: To assess and measure occurrence of sleep disorders in patients with psoriatic arthritis (PsA) and psoriasis (Ps).

Material And Methods: The study included 62 patients with psoriatic arthritis and 52 patients with psoriasis. The measurement of sleep quality was conducted using the Pittsburgh Sleep Quality Index (PSQI), the evaluation of fatigue by the fatigue subscale of the FACIT-F questionnaire and the patient's quality of life by the Health Assessment Questionnaire (HAQ). Read More

View Article
October 2018

A Case of Ostraceous Psoriasis with Psoriatic Arthritis in an AIDS Patient.

Indian J Dermatol 2018 Nov-Dec;63(6):512-514

Department of Dermatology, College of Medicine, Dankook University, Cheonan, Korea.

Human immunodeficiency virus (HIV) infection may present with severe and atypical cutaneous diseases. Psoriasis also can develop in HIV patients associated with immune dysfunction and be presented as more severe and atypical manifestation. Furthermore, treatment of psoriasis in HIV patients can be complex and challenging. Read More

View Article
December 2018

Ascorbic acid derivative DDH-1 ameliorates psoriasis-like skin lesions in mice by suppressing inflammatory cytokine expression.

J Pharmacol Sci 2018 Nov 20. Epub 2018 Nov 20.

Division of Chemotherapy, Kindai University Faculty of Pharmacy, Kowakae 3-4-1, Higashi-Osaka, Osaka, 577-8502, Japan. Electronic address:

Psoriasis is a chronic inflammatory skin disease in which inflammatory cytokines play a major role in its pathogenesis. Because DDH-1, a novel amphipathic ascorbic acid derivative, has been recently shown to reduce inflammatory cytokine expression in human keratinocytes in vitro, we investigated its effect on imiquimod-induced psoriasis-like skin lesions in C57BL/6 mice. We first found that IL-1β and TNF-α mRNA expression was significantly decreased in the skin lesions treated with DDH-1. Read More

View Article
November 2018

Expression of Three Adipokines (Adiponectin, Leptin and Resistin) in Normal Canine Skin: a Pilot Study.

J Comp Pathol 2018 Nov 28. Epub 2018 Nov 28.

Dermatology/Parasitology/Mycology Unit, School of Veterinary Medicine-ONIRIS, University of Nantes, CS 40706, Nantes, France; NP3 Unit, School of Veterinary Medicine-ONIRIS, University of Nantes, CS 40706, Nantes 44307, France. Electronic address:

Adipokines are biologically active cytokines that are mainly produced in adipose tissue. There is evidence, in man and mice, that some adipokines may be secreted in other tissues including the vascular endothelium, epithelia and sebaceous glands. Moreover, modified serum levels of adipokines have been detected in people with acne vulgaris or psoriasis; it is suspected that adipokines could contribute to local and systemic inflammatory conditions. Read More

View Article
November 2018
1 Read

Coexistent central retinal vein and artery occlusion in a patient with psoriasis receiving ustekinumab.

Arch Soc Esp Oftalmol 2018 Nov 29. Epub 2018 Nov 29.

Departmento de Dermatología, Hospital Universitari i Politècnic La Fe, Valencia, España.

A 44 year-old Caucasian male with a history of plaque psoriasis currently being treated with ustekinumab presented with sudden loss of vision in his left eye. Fundus examination showed central retinal vein occlusion coexisting with central retinal artery occlusion. Posterior examination revealed mild polycythemia, being the underlying cause unknown. Read More

View Article
November 2018

Immunolocalization of serpins in the regenerating tail of lizard suggests a role for epidermal and neural barrier formation.

Authors:
Lorenzo Alibardi

Zoology (Jena) 2018 Dec 22;131:1-9. Epub 2018 Sep 22.

Comparative Histolab Padova and Department of Biology, University of Bologna, via Selmi 3, 40126, Bologna, Italy. Electronic address:

Tail regeneration in lizard is stimulated from the apical epidermis and spinal cord, the principal sources of growth factors and signaling proteins that sustain regeneration. Immunolabeling shows that serpins (serine protease inhibitors), which genes are among those most up-regulated during tail regeneration, are prevalently immunolocalized in the regenerating epidermis and ependyma. Western blot detects main protein bands extracted from regenerating tail at 25-27 and 48-52 kDa. Read More

View Article
December 2018

Psoriasis and Hidradenitis Suppurativa: A Large-scale Population-based Study.

J Am Acad Dermatol 2018 Nov 28. Epub 2018 Nov 28.

Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel; Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Background: The coexistence of psoriasis and hidradenitis suppurativa (HS) has been described, but the association between these conditions is yet to be firmly established.

Objectives: To study the association between psoriasis and HS using a large-scale real-life computerized database.

Methods: A cross-sectional study was conducted comparing the prevalence of HS among patients with psoriasis and among age-, sex- and ethnicity-matched control subjects. Read More

View Article
November 2018

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.

Rheumatology (Oxford) 2018 Dec 4. Epub 2018 Dec 4.

Medical Affairs, Janssen Inc., Toronto, ON, Canada.

Objectives: Treat to target recommendations for PsA state that the target of treatment should be remission or, at the very least, low disease activity. Different clinical indexes have been proposed to define these disease states including the minimal disease activity criteria and the Disease Activity Index for PsA (DAPSA) scores, which have 7 and 4-5 domains, respectively. Using a Canadian cohort, the objectives were to calculate the proportion of patients achieving these criteria, their prognostic value and the overall patient impact of these disease states. Read More

View Article
December 2018
2 Reads

Generalized pustular psoriasis complicated with bullous pemphigoid.

Int J Dermatol 2018 Dec 5. Epub 2018 Dec 5.

Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

View Article
December 2018

When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to adalimumab or ustekinumab.

Dermatol Ther 2018 Dec 5:e12793. Epub 2018 Dec 5.

Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy.

Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. Read More

View Article
December 2018

Notch dysregulation and HS: let's talk about Numb.

Br J Dermatol 2018 Dec 4. Epub 2018 Dec 4.

Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Via Pansini 5, Napoli, Italy.

We read with great interest the article by J. W. Frew regarding Notch Dysregulation as an Epiphenomenon in Inflammatory Skin Diseases. Read More

View Article
December 2018
2 Reads

Stat3 activation in epidermal keratinocytes induces Langerhans cell activation to form an essential circuit for psoriasis via IL-23 production.

J Dermatol Sci 2018 Nov 23. Epub 2018 Nov 23.

Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.

Background: Psoriasis is an inflammatory disease associated with aberrant crosstalk between the epidermis and immune system. However, the role of Langerhans cells (LCs) in psoriasis remains controversial.

Objectives: To elucidate whether LCs are functionally involved in the development of psoriasis using a mouse model. Read More

View Article
November 2018

Rhumatisme psoriasique, un diagnostic difficile du fait du polymorphisme clinique.

Rev Prat 2016 May;66(5):527-532

Service de dermatologie, groupe hospitalier Paris Saint-Joseph, Paris, France.

Psoriatic arthritis, a difficult diagnosis due to clinical polymorphism. Psoriatic arthritis (PsA) is a chronic inflammatory spondyloarthritis that occurs in combination with psoriasis. The prevalence is similar to rheumatoid arthritis. Read More

View Article

Complications cutanées de l’obésité.

Rev Prat 2016 Oct;66(8):881-885

Service d'endocrinologie, centre hospitalier de Saint-Denis, Saint-Denis Cedex, France.

Skin complications of obesity. Obesity is associated with a number of skin lesions. It modifies the skin-acting hormones, temperature regulation, skin pressure, immunity and veno-lymphatic vascular systems. Read More

View Article
October 2016

PSORI-CM02 alleviates IMQ-induced mouse dermatitis via differentially regulating pro- and anti-inflammatory cytokines targeting of Th2 specific transcript factor GATA3.

Biomed Pharmacother 2018 Dec 1;110:265-274. Epub 2018 Dec 1.

Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China; Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China. Electronic address:

The IL-17-producing CD4+ T cell and γδT cells play critical roles in the pathogenesis of psoriasis (PS). PSORI-CM02 is a representative herbal formula for the treatment for PS in South China. It was confirmed to improve PS without obvious side effects in the clinic. Read More

View Article
December 2018
2 Reads

Palmar pustular psoriasis associated with teriflunomide treatment.

Mult Scler Relat Disord 2018 Nov 19;27:400-402. Epub 2018 Nov 19.

Neuroimmunology service, FLENI, Montañeses 2325, (1428), Buenos Aires, Argentina.

Background: Cutaneous adverse effects of Teriflunomide have been rarely reported.

Objective And Methods: We report a relapsing remitting multiple sclerosis patient that developed palmar pustular psoriasis within one month of teriflunomide initiation.

Results: Our patient required discontinuation of teriflunomide due to frequent recurrence of pustules with continuous need of local steroid treatment and resolved completely after teriflunomide discontinuation. Read More

View Article
November 2018

Leakage of sweat into the dermo-epidermal junction as a possible trigger for lichen planus lesion development.

Arch Dermatol Res 2018 Dec 3. Epub 2018 Dec 3.

Department of Dermatology, Kyorin University School of Medicine, 6-20-2, Shinkawa Mitaka, Tokyo, 181-8611, Japan.

No previous studies have convincingly linked sweating disturbance with the subsequent development of lichen planus (LP). Therefore, we investigated whether sweating disturbance could be specifically detected in LP lesions and how it could trigger lesion development. We utilized the impression mold technique (IMT), which allows accurate quantification of individual sweat glands/ducts actively delivering sweat in a well-defined location, to evaluate sweating disturbance in LP lesions. Read More

View Article
December 2018
1 Read

Remission of psoriasis during treatment with sorafenib.

JAAD Case Rep 2018 Nov 14;4(10):1065-1067. Epub 2018 Nov 14.

Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.

View Article
November 2018
2 Reads

Toll-Like Receptor 7 Agonist-Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells.

Cell Mol Gastroenterol Hepatol 2019 25;7(1):135-156. Epub 2018 Sep 25.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; Japan Agency for Medical Research and Development, AMED, Tokyo, Japan. Electronic address:

Background & Aims: Psoriasis and inflammatory bowel disease (IBD) are both chronic inflammatory diseases occurring in the skin and gut, respectively. It is well established that psoriasis and IBD have high concordance rates, and similar changes in immune cells and microbiome composition have been reported in both conditions. To study this connection, we used a combination murine model of psoriatic dermatitis and colitis in which mice were treated topically with the Toll-like receptor 7 agonist imiquimod (IMQ) and fed dextran sulfate sodium (DSS). Read More

View Article
September 2018
1 Read

Psoriasis and Depression: The Role of Inflammation.

Actas Dermosifiliogr 2018 Nov 30. Epub 2018 Nov 30.

Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, España.

Psoriasis is a chronic, systemic inflammatory disorder with multiple comorbidities. The most common comorbidities are mental disorders, especially depression, which can interact negatively with psoriasis to produce a dangerous vicious circle. Depression in psoriasis has traditionally been explained as a response to psychosocial factors and impaired quality of life. Read More

View Article
November 2018

Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries.

Int Immunopharmacol 2018 Nov 27;66:260-266. Epub 2018 Nov 27.

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.

Acute lung injury (ALI) due to chemotherapy occurs frequently. It presents a challenge for clinicians managing therapies for different types of cancers. Carfilzomib (Kyprolis™) is a new proteasome inhibitor that shows promise for the treatment of relapsing multiple myeloma. Read More

View Article
November 2018
2 Reads

Anti-IL17 therapies for psoriasis.

Expert Opin Biol Ther 2018 Nov 30. Epub 2018 Nov 30.

a Division of Dermatology , Baylor Scott and White - Dallas , Dallas , TX , USA.

Introduction: Interleukin-17 (IL-17) is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of plaque psoriasis. As a result, focus in clinical trials has undergone a shift towards disease specific targets, with the goals of more effective treatment and reduction in the incidence of serious adverse events. Areas Covered: Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one against the IL-17 receptor (brodalumab) are approved for the treatment of moderate-to-severe plaque psoriasis. Read More

View Article
November 2018
1 Read

Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis

J Drugs Dermatol 2018 Nov;17(11):1211-1218

Objective: To assess the real-world risk of developing adverse medical conditions (AMCs) among patients with psoriasis treated with biologic therapies or conventional systemic/topical therapies (CST/topical). Methods: Adult patients with psoriasis were identified from the Truven MarketScan US claims database (2008 Q3–2015 Q3) and classified into cohorts based on treatment initiated on the index date (adalimumab [ADA], etanercept [ETN], ustekinumab [UST], infliximab [IFX], or CST/topical). Incident AMCs were identified while on treatment from diagnoses recorded in medical claims and included abnormal test results, infections, mental disorders, cardiovascular disease, malignancies (skin and non-skin), and respiratory disease. Read More

View Article
November 2018

Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.

Curr Rheumatol Rev 2018 Nov 29. Epub 2018 Nov 29.

Department of Rheumatology , Covina Arthritis Clinic, Covina, CA. United States.

Psoriasis is a chronic immune-mediated inflammatory dermatologic condition that is often associated with psoriatic arthritis. There are multiple regimens for the treatment of psoriasis including disease modifying anti rheumatics drugs, biologic agents, phototherapy, topical retinoid and steroids creams, as well as apremilast. Apremilast is an oral phosphodiesterase inhibitor that was approved by the FDA in March 2014 for the treatment of psoriatic arthritis and September 2014 for the treatment of moderate to severe plaque psoriasis. Read More

View Article
November 2018
2 Reads

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Arthritis Care Res (Hoboken) 2018 Nov 30. Epub 2018 Nov 30.

ECRI Institute, Plymouth Meeting, Pennsylvania.

Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).

Methods: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. Read More

View Article
November 2018
4 Reads

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Arthritis Rheumatol 2018 Nov 30. Epub 2018 Nov 30.

ECRI Institute, Plymouth Meeting, Pennsylvania.

Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).

Methods: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. Read More

View Article
November 2018
3 Reads